How Many People Die From a UTI Each Year?

Learn the true mortality statistics for UTIs. Understand the physiological progression from a simple infection to life-threatening sepsis.

Urinary tract infections kill roughly 236,000 to 300,000 people worldwide each year, depending on the dataset and year examined. A 2019 analysis of the Global Burden of Disease study estimated about 236,786 deaths, while a more recent analysis covering 2021 put the figure closer to 300,112. That range surprises most people, because UTIs are usually thought of as a painful but treatable nuisance. For the vast majority of otherwise healthy adults, they are. But once a UTI escapes the bladder and enters the bloodstream, or when it strikes someone elderly, immunocompromised, or unable to communicate symptoms clearly, the infection can turn fatal with alarming speed.

The Global Death Toll and Why It Keeps Climbing

The most recent global estimate, drawn from the Global Burden of Disease study through 2021, places annual UTI deaths at about 300,000, with a 190% increase over the figure recorded in 1990. An earlier analysis using 2019 data reported nearly 237,000 deaths and over five million disability-adjusted life-years lost to UTIs globally. The difference between these two estimates reflects both the passage of time and methodological refinements in the underlying data, but the upward trend is consistent across both.

Several forces are pushing the death toll higher. The world’s population is aging, and UTI mortality climbs steeply after about age 65. More people are living with chronic conditions like diabetes and kidney disease that make infections harder to clear. And as discussed later in this article, antibiotic-resistant bacteria are making some UTIs far more dangerous to treat. Countries with lower levels of socioeconomic development bear a disproportionately larger share of the UTI burden, in part because of reduced access to diagnostics, clean water, and effective antibiotics.

Who Dies From UTIs

The typical person who dies from a UTI is not a healthy 30-year-old who waited a few days too long to see a doctor. Mortality is heavily concentrated among older adults, particularly those over 75 or 80. Global data show that death rates and disability from UTIs remain quite low until around age 65 to 75, after which they climb sharply in both men and women. Men over 85 face an especially high risk for both bloodstream infections originating from UTIs and death within 60 days.

One reason older adults are so vulnerable is that their symptoms often look nothing like the classic burning and urgency that younger people experience. Confusion, fatigue, a fall, or simply “not being themselves” may be the only sign of a serious infection. This vagueness leads to diagnostic delays, which give the bacteria time to spread. Each additional year of age past 65 has been linked to roughly a 14% increase in the odds of recurrent UTIs, compounding the risk over time.

The Sex Paradox in UTI Deaths

Women get UTIs far more often than men. The age-standardized incidence rate for women is about 3.6 times higher than for men. Yet when it comes to actually dying from UTIs, the rates between the sexes are surprisingly similar. In other words, women are much more likely to develop a UTI, but a man who does get one faces roughly the same chance of dying from it.

Part of the explanation is anatomy and comorbidity. The infections that kill tend to be complicated UTIs involving structural abnormalities, catheter use, or prostate problems, conditions more common in older men who end up in hospital settings. When a UTI occurs in that context, the playing field levels out. The overall increase in age-standardized mortality between 1990 and 2019 was actually steeper among women at the global level, a trend researchers attribute in part to rising antibiotic resistance in community-acquired infections, which disproportionately affect women.

How a Simple UTI Becomes Lethal

A straightforward bladder infection, sometimes called cystitis, is uncomfortable but almost never deadly. The danger begins when bacteria travel upward to the kidneys, causing pyelonephritis, or enter the bloodstream, which can trigger a body-wide inflammatory crisis called sepsis. About a quarter of all adult sepsis cases originate in the urinary tract, making it one of the most common entry points for this life-threatening condition.

Once sepsis takes hold, mortality rises quickly. The body’s immune response spirals out of control, organs begin to fail, and blood pressure can drop to dangerous levels. Urosepsis can progress from the first abnormal vital signs to organ failure in a matter of hours. This is why early treatment matters enormously: a Swedish study found that high-risk sepsis patients who did not receive the right antibiotic early had a 28-day mortality rate of about 46%, compared with roughly 13% among those who did. The wrong antibiotic, or the right one given too late, was an independent predictor of death with an odds ratio above 10 in the highest-risk group.

The most common culprits behind these bloodstream infections are bacteria that routinely cause UTIs. In England, E. coli bloodstream infections had a case-fatality rate of about 15%, while Klebsiella species and Pseudomonas aeruginosa were even deadlier, at roughly 20% and 26% respectively. These are not exotic organisms. E. coli is responsible for the majority of uncomplicated UTIs worldwide, and when it breaches the urinary tract’s boundaries, the consequences can be severe.

Why Antibiotic Resistance Makes UTI Deaths Harder to Prevent

Antibiotic resistance is quietly making UTIs more dangerous. When the bacterium causing a UTI does not respond to standard first-line antibiotics, the patient may spend days on an ineffective drug while the infection worsens. A multicenter study of patients admitted to emergency departments with UTIs found that infection with a multidrug-resistant pathogen roughly doubled the odds of dying within 30 days, even after adjusting for other risk factors. The only variable more strongly linked to death was the presence of frank sepsis or septic shock.

The pattern holds for specific resistant strains. In a hospital-based comparison, UTIs caused by drug-resistant Klebsiella pneumoniae led to six deaths compared to just one death among patients infected with susceptible strains of the same species, a statistically significant difference. Among hospitalized patients with complicated UTIs in the United States, those harboring bacteria resistant to multiple drug classes spent longer in the hospital and ran up higher costs, though overall mortality rates in that particular dataset were comparable between groups.

Resistance matters most when it delays the right treatment. As the sepsis data above illustrate, getting the wrong antibiotic even for a short window can be the difference between survival and death. In regions where resistance rates are high and laboratory capacity is limited, clinicians may cycle through multiple drugs before landing on one that works, and that delay can be fatal for a frail patient.

Catheter-Associated Infections and Hospital Settings

A large share of serious and fatal UTIs are linked to urinary catheters. Catheters create a direct highway for bacteria to enter the bladder, bypass the body’s natural defenses, and form biofilms that resist both the immune system and antibiotics. In a multicenter retrospective study of nearly a thousand hospitalized patients with complicated UTIs, catheter-associated infections had a treatment failure rate of 40% and a 30-day mortality rate of about 16%, compared with just 2% mortality in patients with pyelonephritis and no catheter.

This means that one of the most effective ways to reduce UTI deaths is deceptively simple: use fewer catheters, and remove them sooner. A classic randomized trial demonstrated this decades ago by comparing standard catheter systems to those with sealed, preconnected junctions designed to prevent bacterial entry. Among patients who were not on systemic antibiotics, the group using standard catheters had a 14% death rate, versus 4% in the sealed-catheter group. The adjusted risk of death was more than three times higher with the standard setup. Hospital infection-control programs now emphasize daily reassessment of whether a catheter is still needed, and many institutions have achieved measurable reductions in catheter-associated UTI rates through these protocols.

UTIs During Pregnancy

Pregnancy changes the urinary tract in ways that make infections both more likely and more dangerous. Hormonal shifts relax the muscles of the ureters, urine flow slows, and the growing uterus can partially obstruct drainage from the kidneys. If a bladder infection progresses to acute pyelonephritis during pregnancy, the stakes rise for both mother and baby. Complications linked to pyelonephritis in pregnancy include preterm birth, preeclampsia, stillbirth, and neonatal infections.

A systematic review of pyelonephritis cases during pregnancy found that nearly half of the mothers who developed complications experienced sepsis, about a third developed anemia, and roughly one in ten suffered acute kidney injury. Maternal death occurred in about 6% of complicated cases. On the fetal side, about 23% of pregnancies in the reviewed cases resulted in preterm delivery, and 6% ended in fetal death. These are figures from complicated cases that made it into case reports, so they likely overrepresent severe outcomes. Still, they underscore why prenatal care in most countries includes routine urine screening, and why even symptomless bacterial colonization of the urine during pregnancy is typically treated with antibiotics.

Spinal Cord Injuries and Other Vulnerable Populations

People with spinal cord injuries face a uniquely high UTI burden. Damage to the spinal cord disrupts normal bladder control, often requiring long-term catheterization or intermittent self-catheterization. UTIs are the most common infection in this population and have been identified as the second leading cause of death among spinal cord injury patients. Making matters worse, diagnosing a UTI in someone who already has abnormal bladder sensations and chronically colonized urine is genuinely difficult. There is no consensus on what distinguishes a true infection from harmless bacterial presence in these patients, so infections may go untreated until they progress to sepsis, or patients may receive unnecessary antibiotics that accelerate resistance.

Other groups with elevated risk include organ transplant recipients on immunosuppressive drugs, people with uncontrolled diabetes, and residents of long-term care facilities where catheter use is common and outbreaks of resistant organisms spread easily. In all of these populations, the underlying theme is the same: the infection gains a foothold that the body cannot clear on its own, and every hour of delay in effective treatment raises the risk of a cascade toward sepsis and death.

Are UTI Deaths Undercounted?

The figures cited above are likely underestimates, for a few reasons. Death certificates typically list the final cause of death rather than the infection that started the chain of events. An older adult who develops a UTI, progresses to urosepsis, and dies of multi-organ failure may have “sepsis” or “renal failure” listed as the primary cause, with no mention of a urinary tract infection at all. Similarly, a hospitalized patient who develops a catheter-associated UTI and then dies of a cardiac arrest triggered by sepsis-related metabolic chaos may not have “UTI” appear anywhere on the death record.

Coding practices also vary widely between countries. In places with less developed health infrastructure, many UTI deaths in older adults likely occur at home and are attributed to old age or other chronic conditions. Even in high-income countries, the move from in-person to telephone consultations for older patients with suspected UTIs during the COVID-19 era may have introduced new diagnostic gaps. All of this suggests that the true number of UTI-attributable deaths globally probably exceeds the roughly 300,000 figure captured in the most recent disease-burden estimates.

What Actually Reduces the Risk

Given that the majority of UTI deaths occur in specific high-risk settings, most prevention strategies focus on those contexts rather than on the general population. For hospitalized and catheterized patients, the evidence strongly supports removing catheters as soon as they are no longer essential. Closed drainage systems, proper catheter hygiene, and daily assessment of catheter necessity are standard recommendations in most hospital infection-control guidelines.

For older adults in the community, the most important intervention is prompt and appropriate antibiotic treatment when a UTI is suspected. The BMJ cohort study noted earlier found that men over 85 were at particularly high risk when treatment was delayed or withheld. Waiting for culture results before starting any antibiotic, a practice sometimes used in younger patients, may not be safe in frail elderly patients showing signs of systemic illness. Clinical guidelines generally recommend starting empiric antibiotics immediately in older adults with suspected UTIs and adjusting the choice once culture results come back.

At the same time, overuse of antibiotics for asymptomatic bacteriuria, where bacteria are present in the urine but the person has no symptoms, is a separate problem. In most populations, treating asymptomatic bacteriuria does not reduce complications and simply drives resistance. Pregnancy is one of the exceptions where treatment of symptomless bacterial colonization is supported by evidence. Striking the balance between treating genuine infections early and not treating harmless colonization with unnecessary antibiotics remains one of the trickier clinical judgment calls in everyday medicine, and getting it wrong in either direction has consequences that eventually show up in the mortality statistics.